» Articles » PMID: 30819830

The Role of Radiation Oncology in Immuno-Oncology

Overview
Journal Oncologist
Specialty Oncology
Date 2019 Mar 2
PMID 30819830
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the promising efficacy of immunotherapy in some patients, many other patients are resistant. The synergistic effect of radiotherapy (RT) in combination with immunotherapy reported in case reports and clinical trials has piqued the interest of radiologists in investigating the underlying mechanisms and efficacy of the combination in preclinical and clinical trials. To date, the reported data are limited to small-sized samples, trials lacking a comparison arm, and trials using diverse immunotherapies, various radiation doses, and fractionations. There are just a few studies comparing the efficacy of immunotherapy and radiotherapy to that of conventional therapies or different combinations. Radiologists should design and conduct clinical trials wisely to confirm the efficacy of the combination, particularly the abscopal effect, identify the best combination of various immunotherapeutic drugs and different radiation models for patients, identify the best sequence of the combination, determine the optimal timing of the combination, select the target site and volume, lower adverse effects, and explore predictive models to identify patients who may benefit from the combination therapy. We expect that these clinical trials performed by radiologists will offer definitive evidence for the wide use of the combination of RT and immunotherapy in clinical practice. IMPLICATIONS FOR PRACTICE: This review will provide an update on the use of a combination of radiotherapy and immunotherapy, a cautious interpretation of preliminary results, and future directions for radiologists to perform well-designed clinical trials.

Citing Articles

Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial.

Zhang K, Wang Q, Cao J, Fan C, Shen W, Xiao Q BMC Cancer. 2025; 25(1):347.

PMID: 40001034 PMC: 11863415. DOI: 10.1186/s12885-025-13758-0.


Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.

Hamza F, Mohammad K Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770433 PMC: 11679356. DOI: 10.3390/ph17121591.


The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma.

Zeng Y, Pu X, He F, Hu C, Zhu H, Huang Y iScience. 2024; 27(7):110219.

PMID: 39021795 PMC: 11253153. DOI: 10.1016/j.isci.2024.110219.


Ionizing Radiation Reduces Head and Neck Squamous Cell Carcinoma Cell Viability and Is Associated with Predictive Tumor-Specific T Cell Responses.

Upadhaya P, Ryan N, Roth P, Pero T, Lamenza F, Springer A Cancers (Basel). 2023; 15(13).

PMID: 37444444 PMC: 10340228. DOI: 10.3390/cancers15133334.


Pretreatment high cholesterol and low neutrophils predict complete pathological response after neoadjuvant short‑course radiotherapy followed by chemotherapy and immunotherapy in locally advanced rectal cancer.

Zhang F, Yu D, Yang J, Zhai M, Li L, Zhao L Oncol Lett. 2023; 26(1):319.

PMID: 37332340 PMC: 10272967. DOI: 10.3892/ol.2023.13905.


References
1.
Chajon E, Castelli J, Marsiglia H, de Crevoisier R . The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. Crit Rev Oncol Hematol. 2017; 111:124-132. DOI: 10.1016/j.critrevonc.2017.01.017. View

2.
Levy A, Massard C, Soria J, Deutsch E . Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016; 68:156-162. DOI: 10.1016/j.ejca.2016.09.013. View

3.
Anderson E, Postow M, Wolchok J, Young R, Ballangrud A, Chan T . Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. J Immunother Cancer. 2017; 5(1):76. PMC: 5644249. DOI: 10.1186/s40425-017-0282-x. View

4.
Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

5.
Kwon E, Drake C, Scher H, Fizazi K, Bossi A, van den Eertwegh A . Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15(7):700-12. PMC: 4418935. DOI: 10.1016/S1470-2045(14)70189-5. View